Treatment of agoraphobia with group exposure in vivo and imipramine.
Treatment of agoraphobia with group exposure in vivo and imipramine.
复制标题
通过体内群体暴露和丙咪嗪治疗广场恐惧症。
DOI：
--
复制
发表时间：
1980
影响因子：
--
通讯作者：
M. Woerner
中科院分区：
文献类型：
--
作者：
C. Zitrin;D. Klein;M. Woerner
在一项随机双盲研究中，76 名 21 至 45 岁的患有广场恐惧症的白人女性接受了体内联合群体暴露和丙咪嗪或安慰剂的治疗。安慰剂组和丙咪嗪组的大多数患者均表现出中度至显着的改善。然而，在报告的四项改善措施中的三项上，丙咪嗪治疗显着优于安慰剂治疗：原发性恐惧症、自发恐慌和整体改善。抑郁症与结果之间呈负相关；也就是说，抑郁程度较高的患者在多项结果指标上的表现都比抑郁程度较低的患者表现更差。将这些患者与先前接受丙咪嗪和想象脱敏治疗的广场恐惧症女性进行比较，显示治疗中途体内暴露具有优越性，但在治疗完成时两组之间没有显着差异。
Seventy-six white agoraphobic women, 21 to 45 years old, were treated with combined group exposure in vivo and imipramine or placebo in a randomized double-blind study. A majority of the patients in both the placebo and imipramine groups showed moderate to marked improvement. However, imipramine therapy was significantly superior to placebo therapy on three of the four reported measures of improvement: primary phobia, spontaneous panic, and global improvement. There was a negative correlation between depression and outcome; ie, the more depressed patients fared worse on several outcome measures than those who were less depressed. A comparison of these patients with agoraphobic women previously treated with imipramine and imaginal desensitization showed a superiority of exposure in vivo midway in treatment, but no significant difference between the two groups at the completion of therapy.